Last edition
News about
XYRA receives a US patent protecting dose-adjusted budiodarone therapy for atrial fibrillation, aiming to reduce stroke and heart failure risk through patient monitoring while offering a safer rhythm-control option.
Seaport Therapeutics receives up to USD 15 million from ARPA-H to develop GlyphCele, a lymphatic-targeted oral therapy designed to treat metabolic disease and pancreatic cancer by restoring gut lymphatic function.
Archimedis Digital Report Finds Indian Pharma Accelerating Digital Transformation of Quality Systems
A study by Archimedis Digital shows Indian pharma companies increasingly adopting cloud, automation and AI-driven quality systems, though digital maturity remains uneven across organisations transitioning from paper-based processes.
HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
Octane Medical Group to Acquire Personalised Medicine Unit from Lonza
Octane Medical Group has signed an agreement to acquire the personalised medicine business of Lonza, including the Cocoon cell-therapy platform. The deal aims to expand Octane’s capabilities in advanced therapies and strengthen its presence in the rapidly growing personalised medicine sector.
West Asia conflict threatens Indian pharma exports with potential INR 5,000 crore hit
Escalating geopolitical tensions in West Asia are beginning to disrupt India’s pharmaceutical export supply chains, with industry estimates warning of potential losses of up to INR 5,000 crore if the situation continues through March.
Merck reports positive Phase III results for Keytruda and Welireg combination in kidney cancer
Phase III LITESPARK-022 trial shows Keytruda plus Welireg significantly improves disease-free survival in patients with clear cell renal cell carcinoma after surgery, reducing recurrence or death risk by 28 percent.
Biocon Academy Launches AI Certificate Programme in Life Sciences
Biocon Academy has launched the Syngene IBAB Certificate Programme in Artificial Intelligence in Life Sciences (SAILS), a first-of-its-kind initiative designed to build future-ready, industry-aligned AI talent for the life sciences sector and strengthen the intersection of biotechnology and digital innovation.
South Africa pushes for local manufacturing of Gilead's HIV prevention drug
Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, could soon be produced in South Africa as the government pushes to expand regional manufacturing and improve access to the therapy.
Ipsen receives positive EMA panel opinion for Ojemda to treat paediatric low-grade glioma
European Medicines Agency’s CHMP recommends conditional approval of Ojemda (tovorafenib) for children with BRAF-altered paediatric low-grade glioma, offering a potential targeted therapy option for relapsed or refractory cases.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy